Immunotherapy cocktail aims to boost breast cancer remission before surgery

NCT ID NCT04373031

Ongoing Disease control Sponsor: Providence Health & Services Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding an immunotherapy drug called IRX 2 to standard pembrolizumab (Keytruda) and chemotherapy can improve outcomes for people with triple-negative breast cancer. The study involves 12 participants who receive the combination before surgery. The main goal is to see if more patients have no cancer left at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab (Keytruda) and IRX 2
What this could lead to: If successful, this combination could increase the chance of eliminating all visible cancer before surgery in triple-negative breast cancer patients.
What could go wrong: This is a small, early-phase trial with only 12 participants, so results may not apply widely. The added immunotherapy may also increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST NEOPLASMS

Contacts and locations

Locations

Providence Portland Medical Center

Portland, Oregon, 97213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.